Skip to main content
VCbacked
Log inGet Started

Eximis Surgical

Louisville, United States

Eximis Surgical develops an enabling technology that allows surgeons to quickly remove large specimens through small incisions.

$15.3M raised
Apr 2023
Venture - Series Unknown
Health CareHospitalMedical Device

Top Investors

Questa Capital ManagementVenture InvestorsOlympusMedTech InnovatorForMED Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Eximis Surgical

How much funding has Eximis Surgical raised?
Eximis Surgical has raised $15.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2023.
Who are Eximis Surgical's investors?
Eximis Surgical's investors include Questa Capital Management, Venture Investors, Olympus, MedTech Innovator, ForMED Ventures.
Where is Eximis Surgical headquartered?
Eximis Surgical is headquartered in Louisville, United States.
What does Eximis Surgical do?
Eximis Surgical develops an enabling technology that allows surgeons to quickly remove large specimens through small incisions.
What stage is Eximis Surgical at?
Eximis Surgical is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Eximis Surgical — Funding & Investors." VCBacked, April 24, 2023, https://www.vcbacked.co/company/eximis-surgical. Accessed June 7, 2026.
APA
VCBacked. (2023). Eximis Surgical — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/eximis-surgical
Wikipedia (cite web)
{{cite web |title=Eximis Surgical — Funding & Investors |url=https://www.vcbacked.co/company/eximis-surgical |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Health Care

View all
Virtuoso Surgical
Nashville
Basata
Phoenix
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Sedivention
Munich$848K